SGLT2 inhibitor empagliflozin could be a new treatment for children with type 2 diabetes: lancet

Published Date: 04 Mar 2023

United States: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, with phase 3 clinical trials showing...

Read Full News

Latest News

Older Drug Reprograms White Blood Cells, Improves Blood Sugar in Type 1 Diabetes

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

Oral GLP-1 Orforglipron Performs Well in Phase 3 T2D Trials

Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.

GLP-1s Tied to Musculoskeletal Benefits in Obesity

Use of GLP-1s vs other antiobesity medications is linked to decreased risk for osteoporosis, fractures, disk degeneration, and osteoarthritis in adults with obesity.

AI Tool Detects Occult Pancreatic Cancer Months in Advance

A new AI model reliably identifies hidden pancreatic ductal adenocarcinoma on routine CT scans months before the clinical diagnosis of the disease.

Use Of GLP-1 Drugs Early in Pregnancy Should Not Cause Alarm, Analysis Suggests

Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is ⁠not a cause for alarm, a large new data...

Skin Disorders in Transgender Patients: Treatment Tips

Dermatologists highlight the risks for acne, hair loss and unwanted hair, and melasma, as well as recent data on hidradenitis suppurativa.

Todays Updates

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Todays Updates

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Latest News

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.

Use of GLP-1s vs other antiobesity medications is linked to decreased risk for osteoporosis, fractures, disk degeneration, and osteoarthritis in adults with obesity.

A new AI model reliably identifies hidden pancreatic ductal adenocarcinoma on routine CT scans months before the clinical diagnosis of the disease.

Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is ⁠not a cause for alarm, a large new data...

Dermatologists highlight the risks for acne, hair loss and unwanted hair, and melasma, as well as recent data on hidradenitis suppurativa.

News All Time

From Taboo to Test: Can Menstrual Blood Aid Diagnosis?

Emerging research suggests that menstrual blood may provide valuable diagnostic and biological insights, with potential applications in cancer screening and endometriosis detection.

Do Corticosteroids Really Raise Gestational Diabetes Risk?

Emerging research says the steroids aren’t a major driver of gestational diabetes, but impacts vary depending on the patient.

Petrelintide Tolerability Could Improve on GLP-1 Challenges

The amylin analog petrelintide reduces body weight with 'placebo-like' tolerability, a phase 2 trial shows.

No Increased Retinopathy Risk Seen With Tirzepatide

No changes in diabetic retinopathy status occurred in high-risk people with type 2 diabetes taking tirzepatide when compared with dulaglutide.

CGM Monitoring Benefits Extend to Non-Insulin-Using T2D

Patients with type 2 diabetes not taking insulin who use continuous glucose monitoring show significant reductions in A1c.

Obesity Meds Improve Patients' Perceived Physical Function

Obesity management medications improve patients' perceived physical function and have a 'modest' impact on an objective functional measure.

GLP-1 QOL Benefits Greatest for Those With Obesity Plus T2D

Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.

Danish Study Links Type 1 Diabetes to Femoral Fractures

Both T1D and T2D are linked to a higher incidence of subtrochanteric or femoral shaft and hip fractures, but after adjusting for age, only the association for T1D remains significant.

Glucose Excursions Drive CGM-A1c Discordance in Monitoring

Discordance between continuous glucose monitoring measures and A1c should not always be interpreted as measurement errors, according to a new study.

Primary Infertility Linked to Earlier Menopause Onset

Women with primary infertility undergo natural menopause earlier than women without infertility.

Exclusive-Cigna Drops Coverage Of GLP-1 Obesity Drugs for Its Own Employees

Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee ⁠health plan effective July 1,...

Phase 3: Rapid Relief in Thyroid Eye Disease With Veligrotug

A five-infusion course of veligrotug is well tolerated and results in rapid improvements in diplopia, proptosis, and disease activity in patients with thyroid eye disease, a phase 3 trial shows.

How Cannabis Compounds May Help Create Weight-Loss Drugs

A new study in mice finds that cannabis extracts improve glucose regulation by improving communication between fat cells and the pancreas.

SGLT2 Inhibitors Cut Kidney Events in Nephrotic Proteinuria

In adults with type 2 diabetes and nephrotic-range proteinuria, SGLT2 inhibitors are linked to lower risks for major adverse kidney events and all-cause mortality than DPP-4 inhibitors.

Gestational Diabetes May Raise Future Retinopathy Risk

In women with diabetes, a history of gestational diabetes is associated with a higher risk for diabetic retinopathy, with risk increasing as gestational diabetes severity increases.

BMI at Age 6 Predicts Obesity Risk in Young Adulthood

BMI at age 6 strongly predicts the risk for overweight and obesity in young adulthood; children with a high BMI and slower growth between ages 2 and 6 have odds similar to peers with an average BMI.